Abigail (Lauterbach) Schmitz
Senior Associate
RA Capital Management
TechAtlas senior associate evaluating biotech opportunities and competitive landscapes.
Bio
Professional summary
Laura Stoppel is a Partner on RA Capital's Investment Team, where she works on both public and private investments. She serves as a board director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals, and CellCentric lists her as an investor director and board member. She previously covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders, and her graduate research investigated synaptic translation in syndromic autism.
Notable companies
Selected portfolio companies the partner has backed
Artiva BiotherapeuticsNimbus TherapeuticsAcumen PharmaceuticalsCellCentricIndapta Therapeutics
Background
Career, education, and skills
Career history
- RA Capital ManagementPartnerPresent
- RA Capital ManagementSenior Associate, TechAtlas
Education
- MITPhD in Neuroscience
- Harvard UniversityBA in Biology and Psychology
Other partners at RA Capital Management
12 more profiles
Adam Prince, MD
Senior Associate, Strategic Initiatives
RA Capital Management
RA Capital TechAtlas senior associate with cardiology and medical training.
Alana MacDonald, Ph.D.
Senior Associate
RA Capital Management
Senior TechAtlas associate focused on biotech diligence, landscapes, and portfolio strategy.
Alejandro Sevilla
Associate
RA Capital Management
Planetary Health associate focused on climate-tech landscapes and investment evaluation.
Alex Miller
Senior Associate, Venture
RA Capital Management
Venture senior associate focused on biotech diligence and portfolio strategy.
Alex T. Zhang
Vice President, Structured Capital
RA Capital Management
Structured Capital VP focused on healthcare and life-sciences credit investments.
Alexander Martinez-Forte
Director, Quantitative Research & Strategy
RA Capital Management
RA Capital director leading quantitative analyses for investment decisions and portfolio management.
Allison Harrigan
Senior Director Corporate Development
RA Capital Management
Raven corporate development leader focused on biotech company creation.
Alyssa Larson
Director, Healthcare Specialist - Investor Relations
RA Capital Management
TechAtlas director supporting healthcare diligence and investor relations.
Ami Thakrar, PhD
Associate
RA Capital Management
TechAtlas associate focused on biotech diligence and program strategy.
Anish K. More
Vice President, Corporate Development
RA Capital Management
Raven corporate-development VP focused on investment evaluation and NewCo creation.
Anurag Kondapalli
Principal
RA Capital Management
Principal investing across public and private healthcare technology and services companies.